Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for case workers for patients seeking at-home care. Photo via Getty Images

Anyone who has had to Google their way to home health care knows that it’s not the best way to get effective help. That’s where MedVendor comes in.

Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for caseworkers for case workers for patients seeking at-home care.

At the height of the COVID-19 pandemic, Chris Hunt was at a loss for how to help patients. He had recently taken on a new role in wound care sales. His company would send dressings directly to patients, but finding someone who could apply and change them was a different matter.

“It was an absolute nightmare using [Google] as a resource because you had all of these out-of-date listings. So it was a 50-50 shot whether that company would even be in business… And so it would be one in every seven, one in every eight calls that I would make that I could actually get ahold of somebody that I could talk to about wound care services,” Chris Hunt recalls.

In 2020, the couple began interviewing developers to take their idea to reality. They incorporated as an LLC in 2021.

Chris Hunt calls the platform a home-care equivalent to Angie’s List or Yelp. Though it’s currently designed for users in the medical field, he says that they are working on crafting MedVendor to be used by the general public as well.

Users input the type of service they’re looking for, then can select multiple individual patient needs to further tailor the search. “It'll give you a short list from that of companies that can service those criteria. And once you've been given that list, then you can filter patient zip code as well as patient insurance plan to then whittle that search further and really get to a granular level in terms of what resources that you want to find,” Chris Hunt explains.

The couple says that their Houston location has been both a blessing and a curse for their burgeoning business, which released the MedVendor platform on October 1. Though Chris Hunt says that cutting his business’ teeth in Southeast Texas, with its expansive medical community “proves your worth and holds a ton of weight. There you can go to other markets and really capitalize.”

However, MedVendor doesn’t want to be known just as a Texas company — the Hunts hope to expand far beyond the Houston area to eventually become a household name.

Ashton Hunt, who was also in medical sales before the couple took the leap to pursue MedVendor full-time, is marketing director for the company. She adds that in Q4 of this year, they plan to release a phone app version of the platform, which will make using it even easier for medical teams.

“Ideally, a case manager or social worker, if they're working on a discharge plan for a patient, they can even be bedside with them with their phone to help find some resources to then pass along to the family or the caregiver,” Chris Hunt says.

Ultimately, the goal of the company, the couple says, is to open up possibilities for patients. By providing up-to-date, vetted information, the hope is that MedVendor will not only supply them with the care they need, but educate them in the process.

- YouTubewww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”

Axiom Space wins NASA contract for fifth private mission, lands $350M in financing

ready for takeoff

Editor's note: This story has been updated to include information about Axiom's recent funding.

Axiom Space, a Houston-based space infrastructure company that’s developing the first commercial space station, has forged a deal with NASA to carry out the fifth civilian-staffed mission to the International Space Station.

Axiom Mission 5 is scheduled to launch in January 2027, at the earliest, from NASA’s Kennedy Space Center in Florida. The crew of non-government astronauts is expected to spend up to 14 days docked at the International Space Station (ISS). Various science and research activities will take place during the mission.

The crew for the upcoming mission hasn’t been announced. Previous Axiom missions were commanded by retired NASA astronauts Michael López-Alegría, the company’s chief astronaut, and Peggy Whitson, the company’s vice president of human spaceflight.

“All four previous [Axiom] missions have expanded the global community of space explorers, diversifying scientific investigations in microgravity, and providing significant insight that is benefiting the development of our next-generation space station, Axiom Station,” Jonathan Cirtain, president and CEO of Axiom, said in a news release.

As part of Axiom’s new contract with NASA, Voyager Technologies will provide payload services for Axiom’s fifth mission. Voyager, a defense, national security, and space technology company, recently announced a four-year, $24.5 million contract with NASA’s Johnson Space Center in Houston to provide mission management services for the ISS.

Axiom also announced today, Feb. 12, that it has secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority.

The company shared in a news release that the funding will support the continued development of its commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

NASA awarded Axiom a contract in January 2020 to create Axiom Station. The project is currently underway.

"Axiom Space isn’t just building hardware, it’s building the backbone of humanity’s next era in orbit," Tarek Waked, Founding General Partner at Type One Ventures, said in a news release. "Their rare combination of execution, government trust, and global partnerships positions them as the clear successor-architect for life after the ISS. This is how the United States continues to lead in space.”